Status:
UNKNOWN
Adaptive Immune Response to COVID-19 Vaccination
Lead Sponsor:
University Medicine Greifswald
Conditions:
SARS-CoV-2 Vaccination
Eligibility:
All Genders
18+ years
Brief Summary
AICOVI (Adaptive Immune Response to COVID-19 Vaccination) is a prospective clinical cohort study aiming at studying the kinetics of vaccine-specific antibody production after COVID-19 vaccination in h...
Detailed Description
AICOVI (Adaptive Immune Response to COVID-19 Vaccination) is a prospective clinical cohort study aiming at elucidating the kinetics of vaccine-specific antibody production after COVID-19 vaccination i...
Eligibility Criteria
Inclusion
- Planned participation in COVID-19 vaccination
- Completion of the 18th year of life
- verbal and written consent given
Exclusion
- current infectious diseases
- underweight (BMI\<18,5)
- blood coagulation disorders, anemia or similar diseases
- known congenital or acquired immunodeficiencies
- Inclusion criteria for control/validation group of TRP participants:
- informed written consent
Key Trial Info
Start Date :
January 6 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 31 2023
Estimated Enrollment :
70 Patients enrolled
Trial Details
Trial ID
NCT04826770
Start Date
January 6 2021
End Date
December 31 2023
Last Update
October 3 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University Medicine Greifswald
Greifswald, Mecklenburg-Vorpommern, Germany, 17475